Octahydro-azulen-2-one | 103274-00-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: Octahydro-azulen-2-one
• 英文别名: Decahydroazulen-2-one；3,3a,4,5,6,7,8,8a-octahydro-1H-azulen-2-one
• CAS: 103274-00-6
• 化学式: C₁₀H₁₆O
• 分子量: 152.236
• InChiKey: JUCWGQDAFCFNEP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  Octahydro-azulen-2-one 在 palladium on activated charcoal 、 乙醚 作用下， 生成 2-propyl-azulene
  参考文献：
  名称：

  对于倍半萜的知识。（第68部分）关于双环-[0，3，5]-癸烷

  摘要：

  DOI：

  10.1002/hlca.19460290324
• 作为产物：
  描述：

  2-[2-(carboxymethyl)cycloheptyl]acetic acid 、 氢氧化钡 以79%的产率得到
  参考文献：
  名称：

  SINGH, MAHATAM;SINGH, GURBAKHSH, INDIAN J. CHEM. A , 29,(1990) N, C. 215-218

  摘要：

  DOI：

文献信息

• [EN] SPIRO-OXAZOLONES<br/>[FR] SPIRO-OXAZOLONES
  申请人：HOFFMANN LA ROCHE

  公开号：WO2015124541A1

  公开（公告）日：2015-08-27

  The present invention provides spiro-oxazolones, which act as V1a receptor modulators, and in particular as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The present compounds are useful as therapeutics acting peripherally and centrally in the conditions of inappropriate secretion of vasopressin, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, aggressive behavior and phase shift sleep disorders, in particular jetlag.

  本发明提供了螺环噁唑酮，其作为V1a受体调节剂，特别是作为V1a受体拮抗剂，其制备方法，含有它们的药物组合物以及它们作为药物的用途。本化合物在周围和中枢作用下，对于不当分泌加压素、焦虑、抑郁症、强迫症、自闭症谱系障碍、精神分裂症、攻击性行为和相位错位性睡眠障碍，特别是时差反应等症状的治疗具有用处。
• 1,3,8-Triaza-spiro 4,5 decan-4-on derivatives
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP0921125A1

  公开（公告）日：1999-06-09

  The present invention relates to compounds of the general formula wherein R1is hydrogen, lower alkyl, halogen, lower alkoxy, trifluoromethyl, lower alkyl-phenyl or (C5-7)-cycloalkyl; R2is hydrogen, lower alkyl, phenyl or lower alkyl-phenyl; R3is hydrogen, lower alkyl, benzyl, lower alkyl-phenyl, lower alkyl-diphenyl, triazinyl, cyanomethyl, lower alkyl-piperidinyl, lower alkyl-naphthyl, (C5-7)-cycloalkyl, lower alkyl-(C5-7)-cycloalkyl, lower alkyl-pyridinyl, lower alkyl-morpholinyl, lower alkyl-dioxolanyl, lower alkyl-oxazolyl or lower alkyl-2-oxo-oxazolidinyl and wherein the ring systems may be substituted by additional lower alkyl, lower alkoxy, trifluoromethyl or phenyl, or -(CH2)nC(O)O-lower alkyl, -(CH2)nC(O)NH2, -(CH2)nC(O)N(lower alkyl)2, -(CH2)nOH or -(CH2)nC(O)NHCH2C6H5; R4is hydrogen, lower alkyl or nitrilo; Ais a ring system, consisting of (a) (C5-15)-cycloalkyl, which may be in addition to R4optionally substituted by lower alkyl, trifluoromethyl, phenyl, (C5-7)-cycloalkyl, spiro-undecan-alkyl or by 2-norbornyl, or is one of the following groups dodecahydro-acenaphthylen-1yl (e), bicyclo[6.2.0]dec-9-yl (f) and bicyclononan-9-yl (g); and wherein R5 and R6are hydrogen, lower alkyl or taken together and with the carbon atoms to which they are attached form a phenyl ring; R7is hydrogen or lower alkyl; the dotted line represents an optional bond and nis 1 to 4; and to pharmaceutically acceptable acid addition salts thereof. Compounds of the present invention are agonists and/or antagonists of the Orphanin FQ (OFQ) receptor. Consequently they will be useful in the treatment of memory and attention deficits, psychiatric, neurological and physiological disorders, especially, but not limited to, amelioration of symptoms of anxiety and stress disorders, depression, trauma, memory loss due to Alzheimer's disease or other dementias, epilepsy and convulsions, acute and/or chronic pain conditions, symptoms of addictive drug withdrawal, control of water balance, Na+ excretion, arterial blood pressure disorders and metabolic disorders such as obesity.

  本发明涉及通式如下的化合物 式中 R1是氢、低级烷基、卤素、低级烷氧基、三氟甲基、低级烷基苯基或(C5-7)-环烷基； R2 是氢、低级烷基、苯基或低级烷基苯基； R3是氢、低级烷基、苄基、低级烷基-苯基、低级烷基-二苯基、三嗪基、氰甲基、低级烷基-哌啶基、低级烷基-萘基、（C5-7）-环烷基、低级烷基-（C5-7）-环烷基、低级烷基-吡啶基、低级烷基-吗啉基、低级烷基-二氧戊环基、低级烷基-噁唑基或低级烷基-2-氧代-噁唑烷基，其中环系统可被额外的低级烷基、低级烷氧基、三氟甲基或苯基取代，或被-(CH2)nC(O)O-低级烷基、-(CH2)nC(O)NH2、-(CH2)nC(O)N(低级烷基)2、-(CH2)nOH 或 -(CH2)nC(O)NHCH2C6H5取代； R4 是氢、低级烷基或硝基； A 是一个环状系统，包括 (a) (C5-15)-环烷基，除 R4 外，还可被低级烷基、三氟甲基、苯基、(C5-7)-环 烷基、螺十一烷基或 2-降冰片基取代，或为以下基团之一 十二氢-苊烯-1-基 (e)、双环[6.2.0]癸-9-基 (f) 和双环壬-9-基 (g)； 其中 R5 和 R6 为氢、低级烷基或与它们所连接的碳原子一起形成苯环； R7 为氢或低级烷基； 虚线代表任选键，且 n为 1 至 4； 及其药学上可接受的酸加成盐。 本发明的化合物是孤儿素 FQ（OFQ）受体的激动剂和/或拮抗剂。因此，它们可用于治疗记忆和注意力缺陷、精神、神经和生理疾病，特别是但不限于改善焦虑和应激障碍、抑郁症、创伤、阿尔茨海默病或其他痴呆症引起的记忆丧失、癫痫和抽搐、急性和/或慢性疼痛、成瘾药物戒断症状、控制水平衡、Na+排泄、动脉血压紊乱和代谢紊乱（如肥胖）等症状。
• Spiro(piperidine-4,1'-pyrrolo(3,4-c)pyrrole)
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP0963987A2

  公开（公告）日：1999-12-15

  The present invention relates to compounds of the general formula    wherein the substituents are described in the application and to pharmaceutically acceptable acid addition salts thereof. The compound of the invention are useful in the treatment of diseases related to the orphanin FQ (OFQ) receptor, which include psychiatric, neurological and physiological disorders, such as anxiety and stress disorders, depression, trauma, memory loss due to Alzheimer's disease or other dementias, deficits in cognition and leaning, epilepsy and convulsions, acute and/or chronic pain conditions, and symptoms of addictive drug withdrawal, control of water balance, Na+ excretion, arterial blood pressure disorders and metabolic disorders such as obesity.

  本发明涉及通式为 其中的取代基见本申请所述，以及其药学上可接受的酸加成盐。 本发明的化合物可用于治疗与孤儿素 FQ（OFQ）受体有关的疾病，这些疾病包括精神、神经和生理疾病，如焦虑和应激障碍、抑郁症、创伤、阿尔茨海默病或其他痴呆症导致的记忆丧失、认知和精益功能障碍、癫痫和抽搐、急性和/或慢性疼痛病症、成瘾性药物戒断症状、水平衡控制、Na+排泄、动脉血压紊乱和代谢紊乱，如肥胖。
• A Facile Conversion of Substituted Cyclobutanones to Cyclopentanones by CH2I2/SmI2 System
  作者：S Fukuzawa

  DOI：10.1016/00404-0399(50)1199r-

  日期：1995.8.14
• GREEN A. E.; DEPRES J.-P., J. AMER. CHEM. SOC., 1979, 101, NO 14, 4003-4005
  作者：GREEN A. E.、 DEPRES J.-P.

  DOI：——

  日期：——